Literature DB >> 3116772

Diagnostic value of thyrotropin-releasing-hormone stimulation in patients with pituitary tumor.

D M Cook, M A Greer, H Paxton.   

Abstract

Plasma prolactin response to thyrotropin-releasing-hormone (TRH) stimulation was diminished in 30 patients with prolactinomas and 9 patients with acromegaly who had normal serum prolactin levels. There was no overlap of prolactin responses when compared with 32 control patients. Responses of ten patients with adrenocorticotropin (ACTH)-secreting pituitary tumors were similar to those of controls. Plasma growth hormone concentrations after TRH stimulation changed significantly in 28% of normal control and 20%, 25% and 50% of patients with prolactin-, growth hormone- and ACTH-secreting pituitary tumors, respectively. Our data suggest that the blunted TRH-induced rise in plasma prolactin levels in patients with prolactinomas and those with acromegaly may be related to humoral factor(s) affecting TRH receptor or postreceptor function. Growth hormone responses to TRH are nonspecific and should not be considered a marker for active acromegaly.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116772      PMCID: PMC1025768     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  38 in total

1.  The dynamics of growth hormone and prolactin secretion in acromegalic patients with "mixed" pituitary tumours.

Authors:  S W Lamberts; J G Klijn; G H Kwa; J C Birkenhäger
Journal:  Acta Endocrinol (Copenh)       Date:  1979-02

2.  Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation.

Authors:  V S Lim; S C Kathpalia; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

3.  Functional delineation of hyperprolactinemic-amenorrhea.

Authors:  G C Lachelin; S Abu-fadil; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1977-06       Impact factor: 5.958

4.  Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism.

Authors:  M Irie; T Tsushima
Journal:  J Clin Endocrinol Metab       Date:  1972-07       Impact factor: 5.958

5.  Functional evaluation of pituitary reserve in patients with the amenorrhea-galactorrhea syndrome utilizing luteinizing hormone-releasing hormone (LH-RH), L-dopa and chlorpromazine.

Authors:  A Zárate; L S Jacobs; E S Canales; A V Schally; A De la Cruz; J Soria; W H Daughaday
Journal:  J Clin Endocrinol Metab       Date:  1973-12       Impact factor: 5.958

6.  Responses to thyrotropin-releasing hormone in patients with renal failure and after infusion in normal men.

Authors:  D Gonzalez-Barcena; A J Kastin; D S Schalch; M Torres-Zamora; E Perez-Pasten; A Kato; A V Schally
Journal:  J Clin Endocrinol Metab       Date:  1973-01       Impact factor: 5.958

7.  Serum prolactin in patients with "functionless" chromophobe adenomas before and after therapy.

Authors:  N A Samaan; M E Leavens; J H Jesse
Journal:  Acta Endocrinol (Copenh)       Date:  1977-03

8.  Galactorrhea-amenorrhea syndrome: diagnosis and therapy.

Authors:  A E Boyd; S Reichlin; R N Turksoy
Journal:  Ann Intern Med       Date:  1977-08       Impact factor: 25.391

9.  Galactorrhea: a study of 235 cases, including 48 with pituitary tumors.

Authors:  D L Kleinberg; G L Noel; A G Frantz
Journal:  N Engl J Med       Date:  1977-03-17       Impact factor: 91.245

10.  Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses.

Authors:  A Liuzzi; P G Chiodini; L Botalla; F Silvestrini; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1974-11       Impact factor: 5.958

View more
  1 in total

Review 1.  Pituitary tumors. Current concepts in diagnosis and management.

Authors:  D C Aron; J B Tyrrell; C B Wilson
Journal:  West J Med       Date:  1995-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.